Australian medicine subsidy tracker

Which medicines Australia funds — and what they cost

script.report tracks every decision the Pharmaceutical Benefits Advisory Committee (PBAC) makes about adding a medicine to the PBS, and the government spend that follows. Outcomes, evidence, ICERs, and prescriptions — all drawn from pbs.gov.au.

PSDs indexed year coverage next PBAC deadline last refresh Freeopen source
Smart Search Ask in plain English or describe a precedent
Ask a question "What was PBAC's concern with the economic model for pembrolizumab?"
Describe a precedent "first-in-class oncology, immature overall survival"
Name a drug or class "HER2-positive breast cancer"
Get sharper answers. Be specific — add therapy area, line of therapy, biomarker, comparator, or outcome; use the documents' own language ("immature OS", "cost-minimisation", "nominated comparator"); keep to one idea per query, then refine. See what's new
Outcome
Year
Therapy
Threaded insights

The decision, the voices & the spend — together

Pro threads the public record with what patients told the PBAC and the real pack-level spend.

Market · spend

GLP-1 agonists

A 146-pack diabetes market (ATC A10B) — GLP-1s lead PBS benefit (~$292M). Patient voice centres on access and tolerability.

Market · voice

Respiratory (asthma / COPD)

272 packs across SABA · LABA · ICS · combos · triples · biologics. Spend concentrates in the combinations; consumer input recurs on treatment burden.

Patient voice

What patients told the PBAC

Verbatim consumer input now on 560+ drug pages — quality of life, access barriers, treatment burden — quoted straight from the record.

The record + the voices + the money — threaded in Pro. Open Pro → · custom reports available
PBS data dashboard
PBAC decisions
unique drugs assessed
Recommended
of all PBAC outcomes
Avg. submissions to listing
across recommended drugs
PBS benefit (latest year)
government outlay, AUD
Scripts dispensed
prescriptions filled
Featured analysis

How drugs come back to PBAC

A drug arrives at PBAC for one use, that's just the beginning. The interesting molecules return — year after year, with new indications. Each spoke is one PBAC submission for the selected drug, sorted clockwise by year, coloured by outcome. Drag the slider to watch the molecule bloom; pick a different drug below.

Featured drugs
Reveal through
Recommended Not recommended Deferred Price · formulation · extension Resubmission after rejection
See all 157 multi-submission drugs →
PBAC outcomes
Recommendation breakdown
All extracted PSDs, by latest decision per drug
Loading…
Source: extracted PBAC PSDs. Latest decision per drug; resubmissions counted within the drug record.
Activity
PSDs published per year
Volume of public summary documents issued by PBAC
Loads with PSD data
Counts only public summary documents indexed in this database. Each PSD = one PBAC consideration.
Cost effectiveness

ICERs and the path to listing

Incremental cost-effectiveness ratios extracted from PSD economic evaluations
ICER distribution
The $75k ceiling, in practice
Base-case ICERs across recommended drugs (AUD per QALY)
Loading ICER distribution…
Lybrand & Wonder (2020) found PBAC has historically not recommended drugs above ~$75,000 AUD/QALY at base case.
Persistence
Submissions to listing
How many PBAC attempts before a drug is recommended
Loading submission counts…
Counted from extracted PSD history. Lybrand & Wonder (2020) reported a mean of 1.70 submissions per recommended drug.
Therapy-area outcomes

Recommendation rate by therapy area

% of unique drugs recommended at the latest PBAC decision
Recommended share
% recommended, by therapy area
Loading…
Includes "Recommended" and "Recommended with restriction" outcomes.
Resubmission rate
% needing more than one attempt
Of recommended drugs, how often the first submission wasn't enough
Loading…
Among recommended drugs only. Therapy areas with <5 recommended drugs are excluded.